Jefferies Financial Group Inc. Purchases 470,096 Shares of Embecta Corp. $EMBC

Jefferies Financial Group Inc. lifted its position in shares of Embecta Corp. (NASDAQ:EMBC) by 24.9% in the fourth quarter, HoldingsChannel reports. The fund owned 2,354,971 shares of the company’s stock after buying an additional 470,096 shares during the period. Jefferies Financial Group Inc.’s holdings in Embecta were worth $27,977,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in EMBC. Ameriprise Financial Inc. raised its position in shares of Embecta by 439.1% during the second quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock worth $6,878,000 after acquiring an additional 578,174 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Embecta during the fourth quarter worth $5,178,000. UBS Group AG raised its position in shares of Embecta by 200.8% during the fourth quarter. UBS Group AG now owns 630,994 shares of the company’s stock worth $7,496,000 after acquiring an additional 421,254 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Embecta by 365.7% during the third quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company’s stock worth $5,255,000 after acquiring an additional 292,477 shares during the last quarter. Finally, LSV Asset Management raised its position in shares of Embecta by 92.5% during the fourth quarter. LSV Asset Management now owns 552,582 shares of the company’s stock worth $6,565,000 after acquiring an additional 265,482 shares during the last quarter. Institutional investors own 93.83% of the company’s stock.

Embecta Price Performance

Shares of Embecta stock opened at $3.32 on Friday. Embecta Corp. has a 1 year low of $2.77 and a 1 year high of $15.55. The business has a 50-day moving average of $7.44 and a two-hundred day moving average of $10.26. The company has a market capitalization of $196.98 million, a P/E ratio of 1.75 and a beta of 1.09.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The business had revenue of $221.80 million during the quarter, compared to the consensus estimate of $235.67 million. During the same quarter last year, the company earned $0.70 earnings per share. The firm’s revenue was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, equities analysts anticipate that Embecta Corp. will post 1.62 EPS for the current fiscal year.

Embecta Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Thursday, May 28th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Thursday, May 28th. Embecta’s dividend payout ratio is currently 31.58%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Bank of America dropped their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a report on Monday, May 18th. Mizuho dropped their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Zacks Research downgraded Embecta from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Finally, BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Strong Sell” and a consensus target price of $11.00.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.